(1) During the three months ended June 30, 2019, we recorded expense of $25.0 million in connection with an upfront payment on a strategic agreement that we entered into with Affibody AB (Affibody). Despite the challenges posed by COVID-19, the Alexion team has continued to deliver. The audio webcast can be accessed on the Investor page of Alexion’s website at: http://ir.alexion.com. We remain focused on continuing to serve patients, protecting the health and safety of our employees and the communities in which we live and work, and supporting patients in clinical trials. (2) During the six months ended June 30, 2020, we recorded $21.5 million in litigation charges in connection with legal proceedings. Information about your device and internet connection, including your IP address, Browsing and search activity while using Verizon Media websites and apps. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. Alexion Pharmaceuticals, Inc.(ALXN Quick Quote ALXN - Free Report) is scheduled to release second-quarter 2020 results on Jul 30, before market … Selling, general and administrative expense: Change in fair value of contingent consideration (3), (Gains) and losses related to strategic equity investments, GAAP earnings (loss) per common share - diluted, Non-GAAP earnings per common share - diluted, Shares used in computing diluted earnings (loss) per common share (GAAP), Shares used in computing diluted earnings per common share (non-GAAP). On a GAAP basis, diluted EPS in the quarter was $(4.84), compared to $2.04 in the prior year. Acquisition-related costs primarily consist of Achillion and Portola transaction costs, costs associated with the accelerated vesting of stock options previously granted to Achillion employees and Achillion restructuring-related costs. BOSTON--(BUSINESS WIRE)--Jul. A replay of the call will be available for a limited period following the call. Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. Media Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the first quarter of 2020. BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the second quarter of 2020. This website is intended only for residents of the United States. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders and cardiology. The second quarter of 2020 includes impairment charges of $2,053.3 million primarily relating to the KANUMA intangible asset as a result of the Company's revised strategic view of KANUMA. To participate in the call, dial 866-762-3111 ( USA ) or 210-874-7712 (International), conference ID 1692605 shortly before 8:00 a.m. Eastern Time . Ladies and gentlemen, thank you for standing by, and welcome to Alexion Pharmaceuticals second-quarter 2020 results conference call. TABLE 3: RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL GUIDANCE, (in millions, except per share amounts and percentages), Diluted non-GAAP earnings per common share, Costs and expenses and margin (% total revenues), Non-GAAP research and development expense, GAAP selling, general and administrative expense, Non-GAAP selling, general and administrative expense, Income tax expense (% of income before income taxes), Tax effect of pre-tax adjustments to GAAP net income, TABLE 5: CONDENSED CONSOLIDATED BALANCE SHEETS, Prepaid expenses and other current assets, Total liabilities and stockholders' equity, TABLE 6: CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS. PDF 346KB Q1 results 2012 – David Brennan (CEO) script . Third-quarter financial results were strong, with 26% revenue … This press release and further information about Alexion can be found at: www.alexion.com. Alexion disclaims any obligation to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law. By using our website, you agree to our use of cookies in accordance with our, Alexion Reports Second Quarter 2020 Results. Updated 2020 financial guidance assumes a GAAP effective tax rate of (27.0) to (26.0) percent and a non-GAAP effective tax rate of 15.5 to 16.5 percent. Non-GAAP diluted EPS for the second quarter of 2020 was $3.11, an 18 percent increase versus the second quarter of 2019. (3) Changes in the fair value of contingent consideration expense for the three and six months ended June 30, 2020 as well as the six months ended June 30, 2019 include the impact of changes in the expected timing of achieving contingent milestones, in addition to the interest component related to the passage of time. BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the first quarter of 2019.Total revenues in the first quarter were $1,140.4 million, a 23 percent increase compared to the same period in 2018. During the six months ended June 30, 2019, we recorded expense of $46.2 million in connection with upfront payments on strategic agreements that we entered into with Affibody and Zealand Pharma A/S. Alexion’s financial guidance is based on current foreign exchange rates net of hedging activities and does not include the effect of acquisitions, license and other strategic agreements, intangible asset impairments, litigation charges, changes in fair value of contingent consideration, gains or losses related to strategic equity investments or restructuring and related activity outside of the previously announced activities that may occur after the issuance of this press release. Alexion Reports Third Quarter 2020 Results * 3Q20 total revenues of $1,588.7 million, a 26% increase over 3Q19 * 3Q20 GAAP diluted EPS of $2.62; … Alexion to Report Fourth Quarter and Full Year 2020 Results on Thursday, February 4, 2021 BOSTON --(BUSINESS WIRE)--Jan. 25, 2021-- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2020 before the US financial markets open on February 4, 2021 . You can change your choices at any time by visiting Your Privacy Controls. We are also focused on minimizing potential interactions that could contribute to the spread of the virus and put additional strain on healthcare systems through the use of innovative virtual means where possible. Alexion Pharmaceuticals, Inc.(ALXN Quick Quote ALXN - Free Report) is scheduled to release third-quarter 2020 results on Oct 29, before market open.The company has … Alexion will host a conference call/audio webcast to discuss the fourth quarter and full year 2017 results, at 10:00 a.m. Eastern Time. Adjustments to reconcile net (loss) income to net cash flows from operating activities: Unrealized (gain) loss on forward contracts, Unrealized gain on strategic equity investments. Despite these challenges, we have delivered another strong quarter and continue to advance our LEAD-EXPAND-DIVERSIFY strategy for long-term value creation," said Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the third quarter of 2020. Total revenues in the third quarter were $1,588.7 million, a 26 percen Alexion Reports Second Quarter 2020 Results * 2Q20 total revenues of $1,444.6 million, a 20% increase over 2Q19 * 2Q20 GAAP diluted EPS of $(4.84); non-GAAP diluted EPS of … Non-GAAP income tax expense for the six months ended June 30, 2019 also excludes certain one-time tax benefits of $95.7 million and $30.3 million associated with a tax election made with respect to intellectual property of Wilson and a release of an existing valuation allowance, respectively. First quarter results 2012. ... Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the fourth quarter and full year of 2020. 2 February 2012. Chris Stevo, 857-338-9309 Alexion Reports Fourth Quarter and Full Year 2020 Results. "As a result of execution and delivery against our objectives, we have entered a new phase of company growth and diversification, which enables us to adjust our capital allocation priorities and return value to shareholders through an expanded stock buyback program. BOSTON--(BUSINESS WIRE)--Jul. Find out more about how we use your information in our Privacy Policy and Cookie Policy. Head of Investor Relations, We use cookies to give you the best online experience. Total revenues in the second quarter … 30, 2020-- Total revenues in the third quarter were $1,588.7 million , a 26 percent increase compared to the same period in 2019. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the second quarter of 2020. TABLE 1: CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS, Cost of sales (exclusive of amortization of purchased intangible assets), Acquired in-process research and development, Amortization of purchased intangible assets, Change in fair value of contingent consideration, Shares used in computing earnings (loss) per common share, TABLE 2: RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS, Upfront payments related to licenses and other strategic agreements (1). "Our teams have demonstrated remarkable resilience and agility in their successful navigation of the uncertain COVID-19 pandemic environment. To participate in the call, dial 866-762-3111 (USA) or 210-874-7712 (International), conference ID 6053185 shortly before 8:00 a.m. Eastern Time. Alexion Pharmaceuticals Inc. for $39 billion in cash ... despite questions around the study results. The company has an excellent track record, delivering an earnings beat in … (5) In the second quarter 2020, we recognized impairment charges of $2,053.3 million, primarily related to our KANUMA intangible asset. Earnings per … The non-GAAP results, determined in accordance with our internal policies, exclude the impact of the following GAAP items (see reconciliation tables below for additional information): share-based compensation expense, fair value adjustment of inventory acquired, amortization of purchased intangible assets, changes in fair value of contingent consideration, restructuring and related expenses, upfront payments related to licenses and other strategic agreements, acquired in-process research and development, impairment of purchased intangible assets, gains and losses related to strategic equity investments, litigation charges, gain or loss on sale of a business or asset, gain or loss related to purchase options, contingent milestone payments associated with acquisitions of legal entities accounted for as asset acquisitions, acquisition-related costs and certain adjustments to income tax expense. Alexion Pharmaceuticals, Inc.’s (ALXN Quick Quote ALXN - Free Report) fourth-quarter adjusted earnings of $2.96 per share comfortably beat the Zacks Consensus Estimate of … Alexion Pharmaceuticals, Inc.ALXN is scheduled to release third-quarter 2020 results on Oct 29, before market open.. This press release contains forward-looking statements, including statements related to: guidance regarding anticipated financial results for 2020 (and the assumptions related to such guidance); our expectations regarding the affects COVID-19 will have on our business and operations, including clinical trials and product supply; the strength of our business and continued growth; the Company's capital allocation strategy; plans to expand the Company's pipeline; future plans for, and the timing for, the commencement of future clinical trials and the expected timing of the receipt of results of certain clinical trials and studies, including clinical programs for ULTOMIRIS, a higher concentration formulation of ULTOMIRIS, a subcutaneous administration of ULTOMIRIS, SOLIRIS, ALXN1840, CAEL-101, AG10, ALXN2040, ALXN2050, ALXN1720, ALXN1830, ANDEXXA and CERDULATINIB; potential benefits of current products and products under development and in clinical trials; plans for development programs with third parties; and Alexion's future clinical, regulatory, and commercial plans for ULTOMIRIS and other products and product candidates. Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, … Alexion Beats on Q4 Earnings Estimates Alexion’s fourth-quarter adjusted earnings of $2.96 per share comfortably beat the Zacks Consensus … Alexion also uses these non-GAAP financial measures to establish budgets, set operational goals and to evaluate the performance of the business. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the second quarter of 2020. To participate in the call, dial 800-239-9838 (USA) or 323-794-2551 (International), passcode 7453141 shortly before 10:00 a.m. Eastern Time. Yahoo is part of Verizon Media. 30, 2020-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the second quarter of 2020. Total revenues in the second quarter were $1,444.6 million, a 20 percent increase compared to the same period in 2019. I am incredibly proud of what we have accomplished so far and am confident that we are well positioned to build on this momentum in the second half of the year.". Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the third quarter of 2020. Shares of the company have decreased 0.4% in the past year against the industry ’s 7.8% rally. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including for example, the risks and uncertainties of … (4) For the three and six months ended June 30, 2020, we recorded $4.6 million and $42.7 million, respectively, of acquisition-related costs in connection with the Achillion Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc. acquisitions. Alexion Pharmaceuticals, Inc. ALXN is scheduled to release third-quarter 2020 results on Oct 29, before market open. The negative impact of foreign currency on total revenues year-over-year was 1 percent, or $15.9 million, inclusive of hedging activities. Total revenues in the second quarter were $1,444.6 million , a 20 percent increase compared to the same period in 2019. For the three months ended June 30, 2019, changes in fair value of contingent consideration expense reflected only the interest component of contingent consideration related to the passage of time. The negative impact of foreign currency on total revenues year-over-year was 1 percent, or $12.3 million, inclusive of hedging activities. Alexion reported revenue in the third quarter of $1.59 billion. In the last reported quarter, Alexion came up with an earnings surprise of 25.1%. Alexion Pharmaceuticals Inc. announced results from an interim analysis of an ongoing Phase 3 open-label extension study of the pivotal, placebo-controlled REGAIN study of Soliris (eculizumab) for the treatment of patients with refractory generalized myasthenia gravis who are anti-acetylcholine rece 26 April 2012. Alexion Pharmaceuticals, Inc.’s ALXN fourth-quarter adjusted earnings of $2.96 per share comfortably beat the Zacks Consensus Estimate of $2.50 and grew from $2.71 in the year-ago period. The 2020 GAAP and non-GAAP tax rates do not benefit from one-time events that benefited the tax rates in 2019. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the third quarter of 2015.Total revenues grew to $666.6 million, a … Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) rose 1.3% in pre-market trading after the company reported Q2 results. Full guidance updates are outlined below. (6) Alexion's non-GAAP income tax expense for the three and six months ended June 30, 2020 and 2019 excludes the tax effect of pre-tax adjustments to GAAP profit. We and our partners will store and/or access information on your device through the use of cookies and similar technologies, to display personalised ads and content, for ad and content measurement, audience insights and product development. The company has an excellent track record, delivering an … Alexion will host a conference call/audio webcast to discuss the second quarter 2020 results today at 8:00 a.m. Eastern Time. Total revenues in the second quarter were $1,444.6 million, a 20 percent increase compared to the same period in 2019. Alexion Pharmaceuticals, Inc. today announced financial results for the first quarter of 2020. Quarterly Results. To enable Verizon Media and our partners to process your personal data select 'I agree', or select 'Manage settings' for more information and to manage your choices. Megan Goulart, 857-338-8634 These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for, or superior to, the financial measures prepared and presented in accordance with GAAP, and should be reviewed in conjunction with the relevant GAAP financial measures. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. PDF 115KB Fourth quarter and full year results 2011. Executive Director, Corporate Communications, Investors On a GAAP basis, diluted EPS in the quarter was $2.50, a 4 percent decrease versus the prior year. Q1 results 2012 presentation . Please refer to the attached Reconciliations of GAAP to non-GAAP Financial Results and GAAP to non-GAAP 2020 Financial Guidance for explanations of the amounts adjusted to arrive at non-GAAP net income and non-GAAP earnings per share amounts for the three and six month periods ended June 30, 2020 and 2019 and projected twelve months ending December 31, 2020. Changes in operating assets and liabilities, excluding the effect of acquisitions: Prepaid expenses, right of use operating assets and other assets, Accounts payable, accrued expenses, lease liabilities and other liabilities, Net cash provided by operating activities, Purchases of available-for-sale debt securities, Proceeds from maturity or sale of available-for-sale debt securities, Purchases of mutual funds related to nonqualified deferred compensation plan, Proceeds from sale of mutual funds related to nonqualified deferred compensation plan, Purchases of property, plant and equipment, Payment for acquisition of business, net of cash acquired, Purchases of strategic equity investments and options, Net proceeds from issuance of common stock under share-based compensation arrangements, Effect of exchange rate changes on cash and cash equivalents and restricted cash, Net change in cash and cash equivalents and restricted cash, Cash and cash equivalents and restricted cash at beginning of period, Cash and cash equivalents and restricted cash at end of period, View source version on businesswire.com: https://www.businesswire.com/news/home/20200730005199/en/, Alexion: GAAP EPS guidance is negatively impacted by the impairment charges recorded during the second quarter 2020. In addition to financial information prepared in accordance with GAAP, this press release also contains non-GAAP financial measures that Alexion believes, when considered together with the GAAP information, provide investors and management with supplemental information relating to performance, trends and prospects that promote a more complete understanding of our operating results and financial position during different periods. Updated 2020 financial guidance includes the impact of the July 2, 2020 acquisition of Portola but excludes the impact of certain GAAP-only purchase accounting items related to the Portola acquisition, including amortization of purchased intangible assets, fair value adjustment of inventory acquired and the related tax effects. Alexion will host a conference call/audio webcast to discuss the first quarter 2019 results today at 8:00 a.m. Eastern Time. We continue to take steps to proactively respond to the evolving COVID-19 pandemic and to plan for related uncertainties. PDF 76KB Q1 results 2012 – Simon Lowth (CFO) script . BOSTON--(BUSINESS WIRE)--Oct. 29, 2020-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the third quarter of 2020. This reflected a 26% increase from the prior-year period revenue total of $1.3 billion. Alexion is increasing total revenues and non-GAAP EPS guidance and decreasing operating margin guidance. Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. © 2021 Alexion Pharmaceuticals, Inc. https://www.businesswire.com/news/home/20200730005199/en/, Diversified commercial-stage portfolio with acquisition of Portola and addition of ANDEXXA, Received EU approval for ULTOMIRIS in atypical hemolytic uremic syndrome (aHUS) & announced positive Phase 3 data for weekly subcutaneous ULTOMIRIS formulation, Updated capital allocation strategy with commitment to return, Increased revenue and non-GAAP EPS guidance to reflect momentum of the business; GAAP EPS guidance negatively impacted by impairment charges. Alexion Reports Fourth Quarter and Full Year 2019 Results 4Q19 total revenues of $1,384.3 million , a 23 percent increase over 4Q18 4Q19 GAAP diluted EPS of $4.00 ; non-GAAP diluted EPS of $2.71 Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ materially from those forward-looking statements, including for example: our dependence on sales from our principal product (SOLIRIS); our ability to facilitate the timely conversion from SOLIRIS to ULTOMIRIS; payer, physician and patient acceptance of ULTOMIRIS as an alternative to SOLIRIS; the impact of the COVID-19 pandemic on Alexion’s business, including its sales, clinical trials, operations and supply chain; appropriate pricing for ULTOMIRIS; future competition from biosimilars and novel products; decisions of regulatory authorities regarding the adequacy of our research, marketing approval or material limitations on the marketing of our products; delays or failure of product candidates to obtain regulatory approval; delays or the inability to launch product candidates due to regulatory restrictions, anticipated expense or other matters; interruptions or failures in the manufacture and supply of our products and our product candidates; failure to satisfactorily address matters raised by the FDA and other regulatory agencies; results in early stage clinical trials may not be indicative of full results or results from later stage or larger clinical trials (or broader patient populations) and do not ensure regulatory approval; the possibility that results of clinical trials are not predictive of safety and efficacy and potency of our products (or we fail to adequately operate or manage our clinical trials) which could cause us to halt trials, delay or prevent us from making regulatory approval filings or result in denial of approval of our product candidates; unexpected delays in clinical trials; unexpected concerns that may arise from additional data or analysis obtained during clinical trials; future product improvements may not be realized due to expense or feasibility or other factors; uncertainty of long-term success in developing, licensing or acquiring other product candidates or additional indications for existing products; inability to complete planned acquisitions due to failure of regulatory approval or material changes in target or otherwise; inability to complete acquisitions and investments due to increased competition for technology; the possibility that current rates of adoption of our products are not sustained; the adequacy of our pharmacovigilance and drug safety reporting processes; failure to protect and enforce our data, intellectual property and proprietary rights and the risks and uncertainties relating to intellectual property claims, lawsuits and challenges against us (including intellectual property lawsuits relating to ULTOMIRIS brought by third parties against Alexion and inter partes review petitions submitted by third parties); the risk that third party payors (including governmental agencies) will not reimburse or continue to reimburse for the use of our products at acceptable rates or at all; failure to realize the benefits and potential of investments, collaborations, licenses and acquisitions, including the acquisition of Portola Pharmaceuticals, Inc.; the possibility that expected tax benefits will not be realized; assessment of impact of recent accounting pronouncements; potential declines in sovereign credit ratings or sovereign defaults in countries where we sell our products; delay of collection or reduction in reimbursement due to adverse economic conditions or changes in government and private insurer regulations and approaches to reimbursement; uncertainties surrounding legal proceedings, company investigations and government investigations; the risk that estimates regarding the number of patients with PNH, aHUS, gMG, NMOSD, HPP and LAL-D and other indications we are pursuing are inaccurate; the risks of changing foreign exchange rates; risks relating to the potential effects of the Company's restructuring; risks related to the acquisition of companies and co-development and collaboration efforts; and a variety of other risks set forth from time to time in Alexion's filings with the SEC, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended March 31, 2020 and in our other filings with the SEC.